OASIS to J&J: Acuvue Oasys is infringement

Article

Glendora, CA?OASIS Medical filed a lawsuit against Johnson & Johnson/Johnson & Johnson Vision Care Inc. (J&J) in the U.S. District Court in the Central District of California, alleging that the companies' use of the name OASYS infringes and dilutes OASIS Medical's trademark rights. Acuvue Oasys with Hydraclear Plus is a trademark of Johnson & Johnson Vision Care Inc. for its line of Acuvue contact lenses.

Glendora, CA-OASIS Medical filed a lawsuit against Johnson & Johnson/Johnson & Johnson Vision Care Inc. (J&J) in the U.S. District Court in the Central District of California, alleging that the companies' use of the name OASYS infringes and dilutes OASIS Medical's trademark rights. Acuvue Oasys with Hydraclear Plus is a trademark of Johnson & Johnson Vision Care Inc. for its line of Acuvue contact lenses.

"Our company spent 18 years developing a reputation for itself under the name 'OASIS,' " said Norman Delgado, president of OASIS Medical. "J&J has adopted the same name for its new contact lenses, which, like OASIS' products, are designed for patients suffering from dry eye. Considering the impact this will have on our company, we believe that we must defend our trademarks and the use of them."

Introduced in August 2005, Acuvue Oasys with Hydraclear Plus is the first daily wear contact lens made from senofilcon A, a new silicone hydrogel material said to be 50% smoother than other silicone hydrogel lenses, according to the company.

Recent Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.